Open
Actively Recruiting
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
About
Brief Summary
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction [NSTEMI] and ST-segment elevation myocardial infarction [STEMI]).
Primary Purpose
Study Type
Phase
Eligibility
Gender
Healthy Volunteers
Minimum Age
Maximum Age
Inclusion Criteria:
- Age greater than or equal to 18 years
- Hospitalized for primary reason of NSTEMI or STEMI due to presumed atherosclerotic disease
Exclusion Criteria:
- Participants requiring invasive hemodynamic and/or vasopressor/inotropic support at the time of screening
- Participants with elevated biomarkers of myocardial injury due to secondary/nonatherosclerotic etiology (eg, sepsis, atrial fibrillation, vasospasm, decompensated heart failure, uncontrolled hypertension, stress induced cardiomyopathy)
Join this Trial
Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
22-5111
Category
Heart/Cardiovascular Diseases
Principal Investigator
Contact
Location
- UCLA Santa Monica
- UCLA Westwood